tetano
Editor, Senior Moderator
Biology (Basel)
. 2020 Jul 22;9(8):E181.
doi: 10.3390/biology9080181.
SARS-CoV-2 Positive Hospitalized Cancer Patients during the Italian Outbreak: The Cohort Study in Reggio Emilia
Carmine Pinto[SUP] 1 [/SUP], Annalisa Berselli[SUP] 1 [/SUP], Lucia Mangone[SUP] 2 [/SUP], Angela Damato[SUP] 1 3 [/SUP], Francesco Iachetta[SUP] 1 [/SUP], Marco Foracchia[SUP] 4 [/SUP], Francesca Zanelli[SUP] 1 [/SUP], Erika Gervasi[SUP] 1 [/SUP], Alessandra Romagnani[SUP] 1 [/SUP], Giuseppe Prati[SUP] 1 [/SUP], Stefania Lui[SUP] 1 [/SUP], Francesco Venturelli[SUP] 2 [/SUP], Massimo Vicentini[SUP] 2 [/SUP], Giulia Besutti[SUP] 5 6 [/SUP], Rossana De Palma[SUP] 7 [/SUP], Paolo Giorgi Rossi[SUP] 2 [/SUP]
Affiliations
Abstract
In the coronavirus disease (COVID-19) pandemic, cancer patients could be a high-risk group due to their immunosuppressed status; therefore, data on cancer patients must be available in order to consider the most adequate strategy of care. We carried out a cohort study on the risk of hospitalization for COVID-19, oncological history, and outcomes on COVID-19 infected cancer patients admitted to the Hospital of Reggio Emilia. Between 1 February and 3 April 2020, a total of 1226 COVID-19 infected patients were hospitalized. The number of cancer patients hospitalized with COVID-19 infection was 138 (11.3%). The median age was slightly higher in patients with cancers than in those without (76.5 vs. 73.0). The risk of intensive care unit (ICU) admission (10.1% vs. 6.7%; RR 1.23, 95% Confidence Interval (CI) 0.63-2.41) and risk of death (34.1% vs. 26.0%; RR 1.07, 95% CI 0.61-1.71) were similar in cancer and non-cancer patients. In the cancer patients group, 89/138 (64.5%) patients had a time interval >5 years between the diagnosis of the tumor and hospitalization. Male gender, age > 74 years, metastatic disease, bladder cancer, and cardiovascular disease were associated with mortality risk in cancer patients. In the Reggio Emilia Study, the incidence of hospitalization for COVID-19 in people with previous diagnosis of cancer is similar to that in the general population (standardized incidence ratio 98; 95% CI 73-131), and it does not appear to have a more severe course or a higher mortality rate than patients without cancer. The phase II of the COVID-19 epidemic in cancer patients needs a strategy to reduce the likelihood of infection and identify the vulnerable population, both in patients with active antineoplastic treatment and in survivors with frequently different coexisting medical conditions.
Keywords: COVID-19; SARS-CoV-2; cancer patients; immunotherapy; lung cancer.
. 2020 Jul 22;9(8):E181.
doi: 10.3390/biology9080181.
SARS-CoV-2 Positive Hospitalized Cancer Patients during the Italian Outbreak: The Cohort Study in Reggio Emilia
Carmine Pinto[SUP] 1 [/SUP], Annalisa Berselli[SUP] 1 [/SUP], Lucia Mangone[SUP] 2 [/SUP], Angela Damato[SUP] 1 3 [/SUP], Francesco Iachetta[SUP] 1 [/SUP], Marco Foracchia[SUP] 4 [/SUP], Francesca Zanelli[SUP] 1 [/SUP], Erika Gervasi[SUP] 1 [/SUP], Alessandra Romagnani[SUP] 1 [/SUP], Giuseppe Prati[SUP] 1 [/SUP], Stefania Lui[SUP] 1 [/SUP], Francesco Venturelli[SUP] 2 [/SUP], Massimo Vicentini[SUP] 2 [/SUP], Giulia Besutti[SUP] 5 6 [/SUP], Rossana De Palma[SUP] 7 [/SUP], Paolo Giorgi Rossi[SUP] 2 [/SUP]
Affiliations
- PMID: 32707770
- DOI: 10.3390/biology9080181
Abstract
In the coronavirus disease (COVID-19) pandemic, cancer patients could be a high-risk group due to their immunosuppressed status; therefore, data on cancer patients must be available in order to consider the most adequate strategy of care. We carried out a cohort study on the risk of hospitalization for COVID-19, oncological history, and outcomes on COVID-19 infected cancer patients admitted to the Hospital of Reggio Emilia. Between 1 February and 3 April 2020, a total of 1226 COVID-19 infected patients were hospitalized. The number of cancer patients hospitalized with COVID-19 infection was 138 (11.3%). The median age was slightly higher in patients with cancers than in those without (76.5 vs. 73.0). The risk of intensive care unit (ICU) admission (10.1% vs. 6.7%; RR 1.23, 95% Confidence Interval (CI) 0.63-2.41) and risk of death (34.1% vs. 26.0%; RR 1.07, 95% CI 0.61-1.71) were similar in cancer and non-cancer patients. In the cancer patients group, 89/138 (64.5%) patients had a time interval >5 years between the diagnosis of the tumor and hospitalization. Male gender, age > 74 years, metastatic disease, bladder cancer, and cardiovascular disease were associated with mortality risk in cancer patients. In the Reggio Emilia Study, the incidence of hospitalization for COVID-19 in people with previous diagnosis of cancer is similar to that in the general population (standardized incidence ratio 98; 95% CI 73-131), and it does not appear to have a more severe course or a higher mortality rate than patients without cancer. The phase II of the COVID-19 epidemic in cancer patients needs a strategy to reduce the likelihood of infection and identify the vulnerable population, both in patients with active antineoplastic treatment and in survivors with frequently different coexisting medical conditions.
Keywords: COVID-19; SARS-CoV-2; cancer patients; immunotherapy; lung cancer.